AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1591947
Drug: Allopurinol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (50 mg orally 4 times a day)
Trial: 1591947
Drug: Dimethyl sulphoxide
RxNorm normalized name: Dimethyl sulphoxide
DrugBank: Dimethyl sulfoxide (DB01093)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dimethyl sulphoxide (DMSO, 500 mg orally 4 times a day)
Trial: 14512398
Drug: Tailored fluorouracil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored fluorouracil, epirubicin, and cyclophosphamide (FEC) therapy for nine courses
Trial: 14512398
Drug: Induction FEC
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction FEC therapy for three courses followed by high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin (CTCb)
Trial: 14512398
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (FEC and CTCb)
Trial: 11249802
Drug: Gabapentin (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (900 to 3,600 mg/day)
Trial: 1888819
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg cimetidine suspension four times daily
Trial: 28578208
Drug: Internet-based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based Cognitive Behavioural Therapy (ICBT)
Trial: 19931380
Drug: Inactivated, subvirion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated, subvirion vaccine containing 15microg of influenza A/H5N1 hemagglutinin (HA) by the intramuscular (IM) route
Trial: 19931380
Drug: Inactivated, subvirion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated, subvirion vaccine containing 45microg of influenza A/H5N1 hemagglutinin (HA) by the intramuscular (IM) route
Trial: 19931380
Drug: Inactivated, subvirion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated, subvirion vaccine containing 3microg of H5 HA by the intradermal (ID) route
Trial: 19931380
Drug: Inactivated, subvirion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated, subvirion vaccine containing 9microg of H5 HA by the intradermal (ID) route
Trial: 19931380
Drug: Inactivated, subvirion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated, subvirion vaccine containing 45microg of H5 HA by the intramuscular (IM) route
Trial: 19931380
Drug: Inactivated, subvirion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated, subvirion vaccine containing 15microg of H5 HA by the intramuscular (IM) route
Trial: 22863058
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g colestyramine
Trial: 22863058
Drug: 12 g
RxNorm normalized name: PEG-12 GLYCERYL LAURATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 g colestyramine
Trial: 22863058
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of colestyramine
Trial: 12615670
Drug: rosiglitazone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone (8 mg)
Trial: 2483004
Drug: Neoadjuvant PVB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant PVB therapy
Trial: 2483004
Drug: Neoadjuvant CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant CAP therapy
Trial: 55648
Drug: Levamisole (1-25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (1-25 mg/kg twice daily for two consecutive days every week)
Trial: 55648
Drug: Levamisole (greater
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (greater than 2-5 mg/kg/day)
Trial: 30983001
Drug: 0.1% triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% triamcinolone acetonide cream with wet wraps
Trial: 30983001
Drug: 0.1% triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% triamcinolone acetonide ointment with wet wraps
Trial: 30983001
Drug: Patient preference
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient preference for ointment
Trial: 23350579
Drug: Fibrin sealant
RxNorm normalized name: FIBRIN SEALANT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin sealant (10 mL of Evicel)
Trial: 21722228
Drug: Acetaminophen (500-1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (500-1000 mg) + Ibuprofen (100-400 mg)
Trial: 21722228
Drug: Ibuprofen (100-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (100-400 mg)
Trial: 21722228
Drug: Acetaminophen (500-1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (500-1000 mg)
Trial: 10620007
Drug: Nutritional supplements
RxNorm normalized name: nutritional supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplements and dietary counselling
Trial: 10620007
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no supplements or specific nutritional advice)
Trial: 1585291
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg twice a day for 10 days
Trial: 1585291
Drug: Erythromycin 500
RxNorm normalized name: erythromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 500 mg six hourly for 10 days
Trial: 4032549
Drug: 3 gm.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 gm. ampicillin intramuscularly in divided doses 1 hour before, at the time of, and 6 hours after catheter insertion (Group 1)
Trial: 21956438
Drug: Intravenously administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously administered 6% v/v ethanol to a target blood alcohol concentration of 0.08%
Trial: 21956438
Drug: Intravenously administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously administered 6% v/v ethanol
Trial: 12322847
Drug: Loratadine plus
RxNorm normalized name: Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loratadine plus Pseudoephedrine Sulfate Repetabs Tables (LTD+PSE Repetabs) (Loratadine 5 mg + Pseudoephedrine 120 mg) twice daily
Trial: 12322847
Drug: loratadine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: loratadine (5 mg) twice daily and pseudoephedrine (60 mg) quarter daily
Trial: 9925128
Drug: 750 mL
RxNorm normalized name: ALCOHOL 750 mL in 1 L TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mL black currant and apple juice
Trial: 9925128
Drug: 1000 mL
RxNorm normalized name: TPN Bag 1000 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mL black currant and apple juice
Trial: 9925128
Drug: 1500 mL
RxNorm normalized name: Bag/Pump Set 1500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mL black currant and apple juice
Trial: 7589375
Drug: Terbutaline and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline and budesonide turbohalers used twice daily over 12 weeks
Trial: 2156387
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated rotavirus vaccine (derived from rhesus rotavirus strain MMU 18006 and human serotype 1 strain Wa)
Trial: 2156387
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated rotavirus vaccine
Trial: 28395659
Drug: Abelmoschus manihot
RxNorm normalized name: ABELMOSCHUS MANIHOT WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abelmoschus manihot (huangkui capsule, 2.5 g, three times per day)
Trial: 28395659
Drug: Losartan potassium
RxNorm normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan potassium (100 mg/d)
Trial: 26802783
Drug: Ranibizumab (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (0.5 mg) + deferred laser (N = 111)
Trial: 26802783
Drug: Ranibizumab (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (0.5 mg) + prompt laser (N = 124)
Trial: 26802783
Drug: Triamcinolone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamcinolone (4 mg) + laser/very deferred ranibizumab (N = 125)
Trial: 22249272
Drug: Gemcitabine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine alone (G)
Trial: 18187961
Drug: E-CMF (adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E-CMF (adjuvant anthracycline-based dose-dense sequential chemotherapy)
Trial: 18187961
Drug: E-T-CMF (adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E-T-CMF (adjuvant anthracycline-based dose-dense sequential chemotherapy)
Trial: 12390062
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (≤325 mg/d)
Trial: 22623392
Drug: MUFA diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MUFA diet (20% daily energy MUFA)
Trial: 22623392
Drug: MED diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MED diet (21% daily energy MUFA)
Trial: 22623392
Drug: SFA diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFA diet (19% daily energy as SFA)
Trial: 19198574
Drug: Daily interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily interferon alpha‐2b (4 MIU s.c. for patients > 65 kg or 0.06 MIU/kg < 65 kg) + ribavirin
Trial: 19198574
Drug: PEG‐interferon alpha‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐interferon alpha‐2b (100 microg s.c. weekly for patients > 65 kg or 1.5 microg/kg weekly for patients < 65 kg) + ribavirin
Trial: 16370079
Drug: Olanzapine (Zyprexa)
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine (Zyprexa) 7.5 mg
Trial: 16370079
Drug: Quetiapine (Seroquel)
RxNorm normalized name: quetiapine Oral Tablet [Seroquel]
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine (Seroquel) 200 mg
Trial: 16370079
Drug: Risperidone (Risperdal)
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone (Risperdal) 1.5 mg
Trial: 16370079
Drug: Ziprasidone (Geodon)
RxNorm normalized name: ziprasidone Injection [Geodon]
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ziprasidone (Geodon) 40 mg
Trial: 16370079
Drug: Perphenazine (Trilafon)
RxNorm normalized name: Perphenazine
DrugBank: Perphenazine (DB00850)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perphenazine (Trilafon) 8 mg
Trial: 15156097
Drug: Chlorpheniramine high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine high dose (12 mg)
Trial: 15156097
Drug: Chlorpheniramine low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine low dose (4 mg)
Trial: 15156097
Drug: Chlorpheniramine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine (both doses)
Trial: 8337193
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment programme in a group setting with components of relaxation, cognitive restructuring, and promotion of well-being
Trial: 8337193
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment programme
Trial: 3709586
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine injection (group A)
Trial: 3709586
Drug: No epidural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No epidural morphine (group B)
Trial: 3169499
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (starting dosage, 2.5 mg/kg.day)
Trial: 31284074
Drug: Low-dose colchicine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose colchicine (0.5 mg daily)
Trial: 27613939
Drug: 4mg nicotine
RxNorm normalized name: nicotine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4mg nicotine lozenge
Trial: 27613939
Drug: 4mg lozenge
RxNorm normalized name: MENTHOL 5.4MG LOZENGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4mg lozenge
Trial: 26003545
Drug: Low tidal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low tidal volume strategy (4 to 6 ml/kg PBW)
Trial: 26003545
Drug: High tidal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High tidal volume strategy (8 to 10 ml/kg PBW)
Trial: 23174860
Drug: α(1)-blockade (prazosin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α(1)-blockade (prazosin, 1 mg/20 kg body wt)
Trial: 21636583
Drug: PI‐free combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PI‐free combination including efavirenz
Trial: 21636583
Drug: PI‐free combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PI‐free combination including nevirapine
Trial: 21636583
Drug: PI‐free combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PI‐free combination including abacavir
Trial: 24843530
Drug: Pregabalin 150-600
RxNorm normalized name: pregabalin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 150-600 mg/day
Trial: 19490035
Drug: Pregabalin 600
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin 600 mg/day fixed-dosage
Trial: 18997444
Drug: epalrestat (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epalrestat (150 mg/day)
Trial: 9261853
Drug: Intravenous hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous hydrocortisone (10 mg/kg/day for 10 days)
Trial: 8300814
Drug: FSH‐HP preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSH‐HP preparation (sp. act. approximately 9000 IU FSH/mg of protein), administered as a single dose of 150 IU by i.v. injection to females and by i.m. and s.c. routes to males.
Trial: 8300814
Drug: Standard urinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard urinary FSH preparation (Metrodin), administered as a single dose of 150 IU by i.v. injection to females and by i.m. and s.c. routes to males.
Trial: 3446307
Drug: Half-dose flupenthixol
RxNorm normalized name: flupenthixol
DrugBank: Flupentixol (DB00875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose flupenthixol decanoate
Trial: 3446307
Drug: Standard-dose flupenthixol
RxNorm normalized name: flupenthixol
DrugBank: Flupentixol (DB00875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose flupenthixol decanoate
Trial: 18845806
Drug: High-dose allopurinol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose allopurinol (300 mg once a day)
Trial: 18845806
Drug: Low-dose allopurinol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose allopurinol (100 mg once a day)
Trial: 16339220
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg/day for 2 weeks
Trial: 15093845
Drug: Intravenous ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac tromethamine
Trial: 10569560
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg avorelin subcutaneous depot
Trial: 10569560
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg avorelin subcutaneous depot
Trial: 8758317
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (75 mg daily, n = 40)
Trial: 6753112
Drug: Pirenzepine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine 0.1 mg.kg-1
Trial: 6753112
Drug: Pirenzepine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine 0.25 mg.kg-1
Trial: 6753112
Drug: Pirenzepine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine 0.5 mg.kg-1
Trial: 6753112
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 mg.kg-1)
Trial: 6753112
Drug: Pirenzepine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (various doses)
Trial: 24800828
Drug: Bivalent killed
RxNorm normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bivalent killed whole-cell oral cholera vaccine
Trial: 11907287
Drug: Intravenous amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amiodarone (for patients with dispatch to drug administration ≤ 24 minutes)
Trial: 11907287
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (for patients with dispatch to drug administration ≤ 24 minutes)
Trial: 2746444
Drug: Chlorhexidine spray,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine spray, applied twice a day
Trial: 2746444
Drug: Chlorhexidine mouthwash,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine mouthwash, rinsed twice a day
Trial: 27686946
Drug: Temozolomide chemotherapy
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide chemotherapy (75 mg/m2 once daily for 21 days, repeated every 28 days for a maximum of 12 cycles)
Trial: 27686946
Drug: Radiotherapy (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy (up to 50.4 Gy; 28 doses of 1.8 Gy once daily, 5 days per week for up to 6.5 weeks)
Trial: 27686943
Drug: Temozolomide chemotherapy
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide chemotherapy
Trial: 20696729
Drug: Early transition
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early transition group (transferred from incubator to open crib at >1600 g)
Trial: 20696729
Drug: Standard transition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard transition group (transferred from incubator to open crib at >1800 g)
Trial: 16313106
Drug: Jiangni Hewei
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jiangni Hewei Decoction (JHD), one dose per day for 8 weeks
Trial: 16313106
Drug: Omeprazole, 20
RxNorm normalized name: Omeprazole, 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole, 20 mg once per day for 8 weeks
Trial: 12893712
Drug: High sodium
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High sodium concentration (680 mg/l)
Trial: 12893712
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium concentration (410 mg/l)
Trial: 9457940
Drug: T (50‐100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T (50‐100 mg IM weekly) + desogestrel (150‐300 microg daily)
Trial: 9457940
Drug: T (50‐100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T (50‐100 mg IM weekly) + levonorgestrel (125‐250 microg daily)
Trial: 27113442
Drug: telephone-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telephone-delivered cognitive behavioural therapy (tCBT)
Trial: 15713598
Drug: Gemcitabine 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1,000 mg/m² on days 1, 8, and 15 of each 28-day cycle (3w4)
Trial: 15713598
Drug: Gemcitabine 1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1,500 mg/m² on days 1 and 8 of each 21-day cycle (2w3)
Trial: 12094857
Drug: Balsalazide (6.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balsalazide (6.75 g daily)
Trial: 22906581
Drug: Hotz plate
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hotz plate treatment
Trial: 22906581
Drug: No Hotz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Hotz plate treatment
Trial: 17324249
Drug: R667 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R667 0.2 mg
Trial: 17324249
Drug: R667 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R667 0.5 mg
Trial: 17324249
Drug: R667 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R667 1 mg
Trial: 15606516
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with narrow filter (580-650 nm) at fluence rate of 30 mW cm(‐2)
Trial: 15606516
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with narrow filter (580-650 nm) at fluence rate of 45 mW cm(‐2)
Trial: 15606516
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with broad filter (580-690 nm) at fluence rate of 50 mW cm(‐2)
Trial: 15606516
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with broad filter (580-690 nm) at fluence rate of 75 mW cm(‐2)
Trial: 15606516
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with cumulative light dose of 40 J cm(‐2)
Trial: 15606516
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with varying fluence rates from 30 to 75 mW cm(‐2)